Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

阿替唑单抗 医学 肿瘤科 内科学 临床终点 多西紫杉醇 转移性尿路上皮癌 人口 化疗 催眠药 性能状态 随机对照试验 癌症 免疫疗法 彭布罗利珠单抗 尿路上皮癌 膀胱癌 环境卫生
作者
Thomas Powles,Ignacio Durán,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Fléchon,Gwénaëlle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui
出处
期刊:The Lancet [Elsevier BV]
卷期号:391 (10122): 748-757 被引量:1281
标识
DOI:10.1016/s0140-6736(17)33297-x
摘要

Background Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this patient population. Methods We conducted this multicentre, open-label, phase 3 randomised controlled trial (IMvigor211) at 217 academic medical centres and community oncology practices mainly in Europe, North America, and the Asia-Pacific region. Patients (aged ≥18 years) with metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy were randomly assigned (1:1), via an interactive voice and web response system with a permuted block design (block size of four), to receive atezolizumab 1200 mg or chemotherapy (physician's choice: vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or 75 mg/m2 docetaxel) intravenously every 3 weeks. Randomisation was stratified by PD-L1 expression (expression on <1% [IC0] or 1% to <5% [IC1] of tumour-infiltrating immune cells vs ≥5% of tumour-infiltrating immune cells [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of prognostic factors (none vs one, two, or three). Patients and investigators were aware of group allocation. Patients, investigators, and the sponsor were masked to PD-L1 expression status. The primary endpoint of overall survival was tested hierarchically in prespecified populations: IC2/3, followed by IC1/2/3, followed by the intention-to-treat population. This study, which is ongoing but not recruiting participants, is registered with ClinicalTrials.gov, number NCT02302807. Findings Between Jan 13, 2015, and Feb 15, 2016, we randomly assigned 931 patients from 198 sites to receive atezolizumab (n=467) or chemotherapy (n=464). In the IC2/3 population (n=234), overall survival did not differ significantly between patients in the atezolizumab group and those in the chemotherapy group (median 11·1 months [95% CI 8·6–15·5; n=116] vs 10·6 months [8·4–12·2; n=118]; stratified hazard ratio [HR] 0·87, 95% CI 0·63–1·21; p=0·41), thus precluding further formal statistical analysis. Confirmed objective response rates were similar between treatment groups in the IC2/3 population: 26 (23%) of 113 evaluable patients had an objective response in the atezolizumab group compared with 25 (22%) of 116 patients in the chemotherapy group. Duration of response was numerically longer in the atezolizumab group than in the chemotherapy group (median 15·9 months [95% CI 10·4 to not estimable] vs 8·3 months [5·6–13·2]; HR 0·57, 95% CI 0·26–1·26). In the intention-to-treat population, patients receiving atezolizumab had fewer grade 3–4 treatment-related adverse events than did those receiving chemotherapy (91 [20%] of 459 vs 189 [43%] of 443 patients), and fewer adverse events leading to treatment discontinuation (34 [7%] vs 78 [18%] patients). Interpretation Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1 (IC2/3). However, the safety profile for atezolizumab was favourable compared with chemotherapy, Exploratory analysis of the intention-to-treat population showed well-tolerated, durable responses in line with previous phase 2 data for atezolizumab in this setting. Funding F Hoffmann-La Roche, Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Owen应助Snail采纳,获得10
刚刚
大橙子发布了新的文献求助10
刚刚
9239完成签到 ,获得积分10
1秒前
量子星尘发布了新的文献求助10
1秒前
songvv发布了新的文献求助10
1秒前
飒飒发布了新的文献求助10
2秒前
慧灰huihui完成签到,获得积分10
2秒前
Star完成签到,获得积分10
4秒前
4秒前
柔弱的不二完成签到,获得积分10
5秒前
无心的枫完成签到,获得积分10
7秒前
djdh完成签到 ,获得积分10
7秒前
肖果完成签到 ,获得积分10
10秒前
哭泣笑柳发布了新的文献求助10
11秒前
CipherSage应助长安采纳,获得10
12秒前
飒飒完成签到,获得积分10
13秒前
RONG完成签到 ,获得积分10
13秒前
落落完成签到,获得积分10
14秒前
Yan完成签到 ,获得积分10
15秒前
15秒前
谨慎的凝丝完成签到 ,获得积分10
16秒前
雨洋完成签到,获得积分10
17秒前
chi完成签到 ,获得积分10
18秒前
还单身的湘完成签到,获得积分10
20秒前
fyjlfy完成签到 ,获得积分10
20秒前
深情安青应助Nayvue采纳,获得10
21秒前
研友_Y59785完成签到,获得积分0
21秒前
Xiaoxiao发布了新的文献求助10
22秒前
初初见你完成签到,获得积分10
29秒前
32秒前
思源应助淡淡月饼采纳,获得20
32秒前
dd完成签到 ,获得积分10
33秒前
Nayvue发布了新的文献求助10
37秒前
未来的幻想完成签到,获得积分10
39秒前
Kvolu29完成签到,获得积分10
40秒前
长理物电强完成签到,获得积分10
41秒前
若安在完成签到,获得积分10
42秒前
完美世界应助潘特采纳,获得10
43秒前
拼搏问薇完成签到 ,获得积分10
43秒前
单薄乐珍完成签到 ,获得积分0
46秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022